publication . Article . Other literature type . 2010

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Martina Beltramello; Katherine L. Williams; Cameron P. Simmons; Annalisa Macagno; Luca Simonelli; Nguyen Than Ha Quyen; Soila Sukupolvi-Petty; Erika Navarro-Sanchez; Paul R. Young; Aravinda M. de Silva; ...
Open Access English
  • Published: 16 Sep 2010 Journal: Cell host and microbe, volume 8, issue 3 (issn: 1931-3128, eissn: 1934-6069, Copyright policy)
Abstract
International audience; Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengue by promoting heterotypic virus entry via Fcγ receptors (FcγR). We immortalized memory B cells from individuals after primary or secondary infection and analyzed anti-DENV monoclonal antibodies (mAbs) thus generated. MAbs to envelope (E) protein domain III (DIII) were either serotype specific or cross-reactive and potently neutralized DENV infection. DI/DII- or viral membrane protein prM-reactive mAbs neutralized poorly and showed broad cross-reactivity with the four DENV serotypes. All mAbs enhanced infection at subneutralizing concentrat...
Subjects
Medical Subject Headings: virusesvirus diseasesbiochemical phenomena, metabolism, and nutrition
free text keywords: [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Virology, Microbiology, Parasitology, Immunology and Microbiology(all), Cancer Research, Molecular Biology, Article, Dengue virus, medicine.disease_cause, medicine, Viral membrane, Biology, Virology, Dengue fever, medicine.disease, Epitope, Viral entry, Secondary infection, Monoclonal antibody, medicine.drug_class, Antibody-dependent enhancement
Funded by
WT
Project
  • Funder: Wellcome Trust (WT)
,
SNSF| The role of innate receptors in dendritic cell and B lymphocyte activation
Project
  • Funder: Swiss National Science Foundation (SNSF)
  • Project Code: 31003AB-126027
  • Funding stream: Project funding | Project funding (Div. I-III)
Communities
COVID-19
75 references, page 1 of 5

Balsitis, S.J., Williams, K.L., Lachica, R., Flores, D., Kyle, J.L., Mehlhop, E., Johnson, S., Diamond, M.S., Beatty, P.R., and Harris, E. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

PLoS Pathog. 6, e1000790.

Beasley, D.W., and Barrett, A.D. (2002). Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76, 13097-13100.

(2001). Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J. Virol. 75, 4002-4007.

Chau, T.N., Quyen, N.T., Thuy, T.T., Tuan, N.M., Hoang, D.M., Dung, N.T., Lien, le B., Quy, N.T., Hieu, N.T., Hieu, L.T., et al. (2008). Dengue in Vietnamese infants-results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J. Infect. Dis. 198, 516-524.

Chau, T.N., Hieu, N.T., Anders, K.L., Wolbers, M., Lien, le B., Hieu, L.T., Hien, T.T., Hung, N.T., Farrar, J., Whitehead, S., and Simmons, C.P. (2009). Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J. Infect. Dis. 200, 1893-1900.

Chin, J.F., Chu, J.J., and Ng, M.L. (2007). The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9, 1-6.

Chu, J.J., Rajamanonmani, R., Li, J., Bhuvanakantham, R., Lescar, J., and Ng, M.L. (2005). Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J. Gen. Virol. 86, 405-412.

Chung, K.M., Nybakken, G.E., Thompson, B.S., Engle, M.J., Marri, A., Fremont, D.H., and Diamond, M.S. (2006). Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 80, 1340-1351.

Crill, W.D., and Chang, G.J. (2004). Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78, 13975- 13986.

Crill, W.D., Hughes, H.R., Delorey, M.J., and Chang, G.J. (2009). Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4, e4991.

Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., et al. (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748.

Falconar, A.K. (1999). Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch. Virol. 144, 2313-2330.

Falconar, A.K. (2007). Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. Clin. Vaccine Immunol. 14, 493-504.

Gibbons, R.V., and Vaughn, D.W. (2002). Dengue: an escalating problem. BMJ 324, 1563-1566.

75 references, page 1 of 5
Any information missing or wrong?Report an Issue